News for 'Sun Pharma'

Wockhardt exits US generics biz, to focus on innovation

Wockhardt exits US generics biz, to focus on innovation

Rediff.com12 Jul 2025

Mumbai-based pharma major Wockhardt, which is gearing up to launch its promising antibiotic candidate Zaynich soon, on Friday announced a shift in its United States (US) operations. The Indian pharma giant revealed that it has decided to exit the generics pharmaceutical segment in the country.

Aurobindo Pharma: Strong prospects offset by valuation concerns

Aurobindo Pharma: Strong prospects offset by valuation concerns

Rediff.com2 Nov 2023

Since the start of this financial year (FY24), the stock of Aurobindo Pharma has been one of the top pharma gainers, enhancing investor wealth by over 68 per cent, with a third of those gains coming in the last three months. The stock is riding on multiple triggers given its investments in the production-linked incentive or PLI scheme, biosimilars, injectables and vaccines, which should drive revenues and profits over the medium term. Better than expected performance after the June quarter results led to a revision of earnings estimates for FY24 and FY25.

India's share in US imports increasing in electronics, agri, textiles: Official

India's share in US imports increasing in electronics, agri, textiles: Official

Rediff.com22 Jul 2025

The restructuring of tariffs by the US has led to a shift in the list of key product suppliers to the American market, with India emerging as one of the beneficiaries at the expense of China and Canada, an official said on Monday. As per an analysis, India's share in the USA's electronics exports has increased to 7.2 per cent to 3.5 per cent year-on-year in May, while China's share dipped to 11 per cent from 22 per cent during the same period.

Israel conflict unlikely to impact trade of pharma firms

Israel conflict unlikely to impact trade of pharma firms

Rediff.com12 Oct 2023

Indian pharmaceutical firms foresee minimal disruptions in trade with Israel despite escalating regional tensions. Rising crude prices and export shipping insurance premiums have raised concerns, but the pharmaceutical sector remains optimistic. Pharmaceutical exports from India to Israel in FY 2020-21 amounted to $32.5 million, which represents only a minor segment of India's overall pharma exports.

Low-income groups to drive branded sugar demand

Low-income groups to drive branded sugar demand

Rediff.com15 Sep 2025

The demand growth in the low-income category is expected to be driven mainly by packaged branded sugar as well as traditionally consumed gur (jaggery) and khandsari.

India's Foreign Policy Panchnama

India's Foreign Policy Panchnama

Rediff.com4 Oct 2025

There has never been a moment in India's history when it has been so adrift in the world, so confused about what it stands for and against and so humiliated, asserts Aakar Patel.

Piyush Goyal urges India Inc to pass on GST benefits to consumers

Piyush Goyal urges India Inc to pass on GST benefits to consumers

Rediff.com4 Sep 2025

Union Commerce and Industry Minister Piyush Goyal on Thursday described the reduction in GST rates as "game-changing" and the "biggest reform" since independence, as he asked the industry to pass on the full benefit to consumers.

Modi meets Xi, Putin, other leaders at SCO Summit reception in Tianjin

Modi meets Xi, Putin, other leaders at SCO Summit reception in Tianjin

Rediff.com31 Aug 2025

Modi was received at the venue by Chinese President Xi Jinping and First Lady Peng Liyuan. On arrival, the Prime Minister exchanged greetings with the Chinese President before joining other leaders for the customary family photo session.

As new GST rates kick in, groceries, medicines, cars get cheaper

As new GST rates kick in, groceries, medicines, cars get cheaper

Rediff.com22 Sep 2025

New lower GST rates kicked in from Monday, resulting in a slashing of prices of as many as 375 items ranging from toothpaste and shampoo to cars and television sets, a move seen as an attempt to boost consumption to cushion an economy facing tariff headwinds. Tax rates of 5, 12, 18, and 28 per cent have been clubbed into two rates of 5 per cent and 18 per cent, resulting in a reduced price of 99 per cent of daily use items.

What July's Hiring Trends Reveal

What July's Hiring Trends Reveal

Rediff.com21 Aug 2025

Fresher hiring grew by 8 per cent driven by non-IT services oil and gas, real estate, and education sectors.

HSBC flags 5 positives for Indian equities

HSBC flags 5 positives for Indian equities

Rediff.com3 Sep 2025

Equity benchmarks face a key test as investors weigh consumption revival hopes against tariff pressures and weak earnings. Amidst this, HSBC has outlined tailwinds and risks that could cap gains.

Sensex falls by 160 pts on sell-off in IT, healthcare shares

Sensex falls by 160 pts on sell-off in IT, healthcare shares

Rediff.com6 Aug 2025

Among the Sensex firms, Sun Pharmaceuticals, Tech Mahindra, HCL Technologies, Infosys, Bajaj Finance, Eternal, Tata Consultancy Services, UltraTech Cement, Bajaj Finserv, Tata Steel, ITC and L&T were the major laggards. Asian Paints, Mahindra & Mahindra, BEL, Adani Ports, State Bank of India, Trent, HDFC Bank were among the gainers.

Sensex, Nifty end in red on concerns over US tariff

Sensex, Nifty end in red on concerns over US tariff

Rediff.com31 Jul 2025

Equity benchmark indices Sensex and Nifty ended lower on Thursday after US President Donald Trump announced the imposition of a 25 per cent tariff on all goods coming from India starting August 1 and an unspecified penalty for buying Russian crude oil and military equipment.

Apollo eyes 20-23% growth in new co; says restructuring to unlock value

Apollo eyes 20-23% growth in new co; says restructuring to unlock value

Rediff.com2 Jul 2025

Apollo Hospitals Enterprise Ltd (AHEL) on Tuesday said its ongoing restructuring aims to unlock the value of its omni-channel pharmacy and digital businesses, while enhancing shareholder returns. The newly-formed entity is expected to achieve a year-on-year growth rate of 22-23 per cent, driven by the e-pharmacy segment and other business verticals, with a revenue target of Rs 25,000 crore by the financial year 2027.

'Where There Is So Much Infrastructure Creation, There Will Be Debt'

'Where There Is So Much Infrastructure Creation, There Will Be Debt'

Rediff.com26 Aug 2025

'We have created massive infrastructure in the past six years.'

Indian pharma exports to Iran decline thanks to its lower rupee reserves

Indian pharma exports to Iran decline thanks to its lower rupee reserves

Rediff.com3 Oct 2023

India's pharmaceutical exports to Iran have been hit owing to depleting rupee reserves in the West Asian country because of India stopping the import of crude oil from it in 2019 following US sanctions. Pharmaceutical exports dropped 71.25 per cent in April-August this year over the same period last year. The data from the Pharmaceutical Exports Promotion Council (Pharmexcil) showed exports to Iran had declined 31.29 per cent in 2022-23 as against the previous financial year.

'Trump Is Frustrated'

'Trump Is Frustrated'

Rediff.com4 Aug 2025

'What India has done will surely embolden more countries to stand up to Trump.'

Sensex pares losses, ends up 64 points

Sensex pares losses, ends up 64 points

Rediff.com16 Jul 2025

Among Sensex firms, Mahindra & Mahindra, Tech Mahindra, State Bank of India, Infosys, Adani Ports and ITC were the major gainers. However, Eternal, Sun Pharma, Tata Steel, Tata Motors, Bajaj Finance and Bharat Electronics were among the major laggards.

Q3 result preview: US, India to aid revenue growth for Pharma Inc

Q3 result preview: US, India to aid revenue growth for Pharma Inc

Rediff.com30 Jan 2024

The pharmaceuticals sector is expected to post a revenue growth of around 13.5 per cent and a net profit growth of 30.3 per cent for the third quarter of 2023-24 (FY24), riding on the approval for niche drugs in the US market, fall in raw material prices and correction in shipping rates. In the healthcare segment, hospitals are expected to post revenue growth of 13 per cent during the coverage, while net profit growth would be around 37 per cent, ICICI Securities said in a note. However, the performance may not be comparable on a sequential basis due to the offset of the festive season in Q3FY24, the analysts noted.

Sensex tanks 586 points on global sell-off

Sensex tanks 586 points on global sell-off

Rediff.com1 Aug 2025

Tata Steel, Maruti, Tata Motors, Infosys, Bharti Airtel and Tech Mahindra were also among the laggards. However, Trent, Asian Paints, Hindustan Unilever, ITC, Kotak Mahindra Bank, and Reliance Industries were the gainers.

US drug shortage, stable pricing set to boost pharma revenues

US drug shortage, stable pricing set to boost pharma revenues

Rediff.com24 Jul 2023

An acute drug shortage in the US and stable pricing along with product launches are likely to boost revenues of India's pharmaceutical companies during the first quarter of this financial year, analysts said. Most brokerages estimate a top line growth of around 14-15 per cent, with earnings before interest, taxes, depreciation, and amortisation (Ebitda) growth of 24-30 per cent for Q1 of FY24. Hospitals are, however, likely to report lower occupancy rates, and diagnostics companies may witness an impact from delayed monsoon.

Sensex gains 320 points; Nifty ends above 24K

Sensex gains 320 points; Nifty ends above 24K

Rediff.com29 May 2025

Benchmark stock indices Sensex and Nifty rebounded on Thursday after two days of decline, mirroring a rally in global markets as a US court blocked President Donald Trump's reciprocal tariffs. The 30-share BSE Sensex climbed 320.70 points or 0.39 per cent to settle at 81,633.02.

Sensex tanks 721 pts dragged by Bajaj Finance, foreign fund outflows

Sensex tanks 721 pts dragged by Bajaj Finance, foreign fund outflows

Rediff.com25 Jul 2025

Stock markets declined for the second day in a row on Friday, with the Sensex tumbling 721 points due to heavy selling in financial, IT and oil & gas shares amid persistent foreign fund outflows.

Blue-chip stocks drag Sensex down by 542 points

Blue-chip stocks drag Sensex down by 542 points

Rediff.com24 Jul 2025

From the Sensex firms, Trent, Tech Mahindra, Bajaj Finserv, Reliance Industries, Infosys, Kotak Mahindra Bank, HCL Technologies, and NTPC were among the biggest laggards. However, Eternal, Tata Motors, Sun Pharma, Tata Steel, and Titan were the gainers.

India-China trade: Deficit widens to $99.2 bn

India-China trade: Deficit widens to $99.2 bn

Rediff.com30 Aug 2025

The bilateral trade between India and China has been growing at a healthy rate, but the trade gap remains sharply tilted in Beijing's favour. India has time and again flagged its concern over the ballooning trade deficit and the non-trade barriers faced by Indian goods in the Chinese market.

India, US Push To Futureproof Trade Ties

India, US Push To Futureproof Trade Ties

Rediff.com29 Jul 2025

India is seeking either an exemption or a longer timeline on the pharmaceutical tariffs, expected to kick in by July 31.

Kerala's SMA Treatment Model Offers Hope

Kerala's SMA Treatment Model Offers Hope

Rediff.com2 Sep 2025

The Kerala model is crucial as SMA patients in India had a long wait for a viable treatment option.

India may emerge as second-largest economy by 2038

India may emerge as second-largest economy by 2038

Rediff.com28 Aug 2025

India's economy could reach $20.7 trillion in terms of purchasing power parity (PPP) by 2030 and may emerge as the second-largest economy by 2038 with $34.2 trillion GDP, an EY report said on Wednesday. The report also said that with appropriate countermeasures, India can limit the adverse impact of higher US tariffs on selected Indian imports to about 10 basis points of real GDP growth.

Buying in L&T helps Sensex gain 144 points

Buying in L&T helps Sensex gain 144 points

Rediff.com30 Jul 2025

Sun Pharma, NTPC, Maruti, Bharti Airtel, Trent and Axis Bank were also among the gainers. However, Tata Motors, Power Grid, Eternal, Bajaj Finserv and Hindustan Unilever were among the laggards.

What is Schedule M and why it's mandatory for all pharma units

What is Schedule M and why it's mandatory for all pharma units

Rediff.com12 Jul 2023

With an eye on improving quality assurance in the wake of increased global scrutiny on Indian pharma products, the Centre on Tuesday said that Schedule M of the Drugs and Cosmetics Act, 1940 will be made compulsory for small and medium scale manufacturers in a phased manner. Union Health Minister Mansukh Mandaviya has asked micro-small and medium enterprises in pharma manufacturing to move towards good manufacturing practices (GMP) through self regulation. "This will help in quality assurance and also reduce compliance burden," Mandaviya.

Stock markets weather Trump tariff storm

Stock markets weather Trump tariff storm

Rediff.com7 Aug 2025

Among Sensex firms, Tech Mahindra, HCL Tech, Eternal, Axis Bank, Maruti, Tata Steel, HDFC Bank and Asian Paints were the gainers. However, Adani Ports, Trent, Tata Motors, Hindustan Unilever and NTPC were among the laggards.

Stock markets end flat in volatile trade

Stock markets end flat in volatile trade

Rediff.com14 Aug 2025

Among Sensex firms, Eternal, Infosys, Asian Paints, HDFC Bank, Bajaj Finserv and Titan were the major gainers. However, Tata Steel, Tech Mahindra, Adani Ports and Bharat Electronics were among the laggards.

Andhera Review: Absurd

Andhera Review: Absurd

Rediff.com14 Aug 2025

It is sporadically chilling but the disparate elements take forever to come together, notes Deepa Gahlot.

Govt to Monitor Non-Essential Drug Prices

Govt to Monitor Non-Essential Drug Prices

Rediff.com28 Jul 2025

The National Pharmaceutical Pricing Authority will monitor how companies are increasing prices of non-scheduled drugs.

Stock markets end lower amid Israel-Iran conflict, rising crude oil prices

Stock markets end lower amid Israel-Iran conflict, rising crude oil prices

Rediff.com17 Jun 2025

From the Sensex pack, Sun Pharma, Eternal, Tata Motors, Bajaj Finance, IndusInd Bank and Bajaj Finserv were among the major laggards. In contrast, Tech Mahindra, Infosys, Asian Paints and Maruti were among the gainers.

India business to put a spring in pharma's step

India business to put a spring in pharma's step

Rediff.com26 Apr 2023

Hospitals to recover from sluggish Q3; diagnostics' growth rate at pre-Covid levels.

Sensex decline on fag-end selling; financial stocks drag

Sensex decline on fag-end selling; financial stocks drag

Rediff.com3 Jul 2025

Among the Sensex firms, Kotak Mahindra Bank, Bajaj Finserv, Bajaj Finance, Adani Ports, Trent, State Bank of India, Titan and Tata Consultancy Services were the laggards. However, Maruti, Infosys, NTPC, Asian Paints, Eternal and Hindustan Unilever were among the biggest gainers.

T'gana plant blast: 9 still missing; cause yet to be known

T'gana plant blast: 9 still missing; cause yet to be known

Rediff.com3 Jul 2025

Nine people remain missing following the explosion at the Sigachi Industries' pharma plant in Pashamylaram, Telangana, which claimed 38 lives. An expert committee is investigating the cause of the blast.

How the markets will fare this week

How the markets will fare this week

Rediff.com27 Jul 2025

Stock markets are in for an event-heavy week ahead with a raft of Q1 earnings from blue-chips, the US Fed interest rate decision and foreign investors trading activity driving investors' sentiment, analysts said. Macroeconomic data announcements, monthly auto sales numbers and global market trends would also guide movement in the domestic equities, they said.

Why Trust In Ambani, Adani, India Inc Is Vital

Why Trust In Ambani, Adani, India Inc Is Vital

Rediff.com12 Sep 2025

Who else will take on the might of Microsoft, Google, and Amazon if not the Adanis, Ambanis, Birlas, or Tatas?, asks R Jagannathan.